Billionaire investor Bill Ackman is launching a high-profile IPO for his closed-end fund, targeting $5-10 billion and aiming to transform Pershing Square into a Berkshire Hathaway-like entity for retail investors.
Goldman Sachs reported strong quarterly earnings, driven by outperforming equities trading and investment banking divisions, though fixed-income trading was weaker than expected.
Geopolitical volatility is seen as a tailwind for trading desks.
A new startup, PureTrace Labs, is commercializing a university-developed technology for rapid, low-cost testing of PFAS ('forever chemicals') in drinking water, addressing a major public health concern affecting up to 50% of Americans.
The IPO market shows signs of life but faces headwinds from market volatility.
While 2026 is anticipated to be a very strong year for major listings, near-term deals face uncertainty, as seen in a recent fundraising shortfall for a Robinhood-backed fund.
12 quotes
Concerns Raised
Geopolitical and market volatility could derail the nascent recovery in the IPO and M&A markets.
Ackman's IPO faces execution risk, as evidenced by a recent fundraising shortfall for a similar fund from Robinhood.
Widespread PFAS contamination in drinking water represents a significant and costly public health crisis.
Opportunities Identified
Bill Ackman's Pershing Square IPO offers retail investors a new way to access his long-term, large-stake investment strategy.
Heightened market volatility is creating a highly profitable environment for bank trading desks, particularly in equities.
PureTrace Labs' technology addresses a large, underserved market for fast and affordable environmental testing.
The 2026 IPO market is poised to be exceptionally strong, with major companies like SpaceX and Anthropic potentially going public.